Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by L...
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 440
- Registration Number
- NCT06569823
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 200
- Registration Number
- NCT05506969
- Locations
- 🇺🇸
Optimal Research Alabama, Huntsville, Alabama, United States
🇺🇸Optimal Research Illinois, Peoria, Illinois, United States
🇺🇸Optimal Research Maryland, Rockville, Maryland, United States
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT05245838
- Locations
- 🇦🇺
Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia
🇦🇺Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 119
- Registration Number
- NCT03934736
- Locations
- 🇺🇸
DaVita Clinical Research or Affiliate, Milwaukee, Wisconsin, United States
DV2-HBV-27: Observational Pregnancy Registry
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT03664648
- Locations
- 🇺🇸
PPD Registry Office, Recruiting Nationwide, Wilmington, North Carolina, United States
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03326752
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Ronald Reagan University of California Los Angeles Medical Center, Santa Monica, California, United States
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT02521870
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Cancer Center - Northside Hospital Central Research Department, Atlanta, Georgia, United States
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02266147
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Stanford University School of Medicine, Stanford, California, United States
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 8374
- Registration Number
- NCT02117934
- Locations
- 🇺🇸
Clinical Research Advantage, Inc., Plano, Texas, United States
🇺🇸Clinical Research Advantage, Inc, Evansville, Indiana, United States
🇺🇸Radiant Research, Murray, Utah, United States
A Study of the Immune Response to Heplisav in Healthy Older Adults
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT01999699
- Locations
- 🇺🇸
Johnson County Clinical Trials, Lenexa, Kansas, United States